International Journal of Radiation Oncology * Biology * Physics
Volume 82, Issue 2 , Pages 524-531 , 1 February 2012

Concomitant Cisplatin and Hyperfractionated Radiotherapy in Locally Advanced Head and Neck Cancer: 10-Year Follow-Up of a Randomized Phase III Trial (SAKK 10/94)

Presented in part at the 52th Annual meeting of the American Society for Radiation Oncology, San Diego, California, October 31th - November 4th, 2010.

  • Pirus Ghadjar, M.D.

      Affiliations

    • Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland, 3010 Bern, Switzerland
    • Corresponding Author InformationReprint requests to: Pirus Ghadjar, M.D., Department of Radiation Oncology, Inselspital, Bern University Hospital, Freiburgstrasse, 3010 Bern, Switzerland. Tel: (+41) 31 632 2431; Fax: (+41) 31 382 2342
    • ,
  • Mathew Simcock, M.Sc.

      Affiliations

    • Swiss Group for Clinical Cancer Research Coordinating Center (SAKK CC), 3008 Bern, Switzerland
    • ,
  • Gabriela Studer, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland
    • ,
  • Abdelkarim S. Allal, M.D.

      Affiliations

    • Department of Radiation Oncology, Kantonsspital Fribourg, Fribourg, Switzerland
    • ,
  • Mahmut Ozsahin, M.D., Ph.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital Lausanne, Lausanne, Switzerland
    • ,
  • Jacques Bernier, M.D.

      Affiliations

    • Department of Radiation Oncology, Clinique de Genolier, Genolier, Switzerland
    • ,
  • Michael Töpfer, M.D.

      Affiliations

    • Department of Radiation Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland
    • ,
  • Frank Zimmermann, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital Basel, Basel, Switzerland
    • ,
  • Michael Betz, M.D.

      Affiliations

    • Department of Radiation Oncology, Geneva University Hospital, Geneva, Switzerland
    • ,
  • Christoph Glanzmann, M.D.

      Affiliations

    • Department of Radiation Oncology, University Hospital Zürich, Zürich, Switzerland
    • ,
  • Daniel M. Aebersold, M.D.

      Affiliations

    • Department of Radiation Oncology, Inselspital, Bern University Hospital, and University of Bern, Switzerland, 3010 Bern, Switzerland
    • ,
  • Swiss Group for Clinical Cancer Research (SAKK)

Received 24 June 2010 ,Revised 5 November 2010 ,Accepted 12 November 2010.

References 

  1. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: A meta-analysis. Lancet. 2006;368:843–854
  2. Pignon JP, le Maître A, Maillard E, et al. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): An update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4–14
  3. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798–1804
  4. Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: A prospective randomized trial. J Clin Oncol. 2000;18:1458–1464
  5. Huguenin P, Beer KT, Allal A, et al. Concomitant cisplatin significantly improves locoregional control in advanced head and neck cancers treated with hyperfractionated radiotherapy. J Clin Oncol. 2004;22:4665–4673
  6. Budach V, Stuschke M, Budach W, et al. Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 prospective randomized trial. J Clin Oncol. 2005;23:1125–1135
  7. Bensadoun RJ, Bénézery K, Dassonville O, et al. French multicenter phase III randomized study testing concurrent twice-a-day radiotherapy and cisplatin/5-fluorouracil chemotherapy (BiRCF) in unresectable pharyngeal carcinoma: results at 2-years (FNCLCC-GORTEC). Int J Radiat Oncol Biol Phys. 2006;64:983–994
  8. Cox JD, Stetz J, Pajak TF. Toxicity criteria of the Radiation Therapy Oncology Group (RTOG) and the European Organization for Research and Treatment of Cancer (EORTC). Int J Radiat Oncol Biol Phys. 1995;31:1341–1346
  9. Forastiere AA, Goepfert H, Maor M, et al. Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med. 2003;349:2091–2098
  10. Beer KT, Greiner RH, Aebersold DM, et al. Carcinoma of the oropharynx: local failure as the decisive parameter for distant metastasis and survival. Strahlenther Onkol. 2000;176:16–21
  11. Ang K, Pajak T, Wheeler R, et al. A phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas (RTOG 0129): Report of efficacy and toxicity. Int J Radiat Oncol Biol Phys. 2010;77:1–2

 Conflict of interest: none.

PII: S0360-3016(10)03695-3

doi: 10.1016/j.ijrobp.2010.11.067

International Journal of Radiation Oncology * Biology * Physics
Volume 82, Issue 2 , Pages 524-531 , 1 February 2012

Article Tools

* Image Usage & Resolution